切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2011, Vol. 05 ›› Issue (04) : 426 -433. doi: 10.3877/cma.j.issn.1674-0807.2011.04.006

临床研究

骨桥蛋白在浸润性乳腺癌组织中的表达及其与微血管密度的关系
隋金珂1, 王玥2, 施俊义(), 谢轶群3, 李曦洲1   
  1. 1.200433 上海,第二军医大学附属长海医院普外科
    2.030001 太原,解放军264 医院普外科
    3.200433 上海,上海市黄浦区中心医院乳腺外科
  • 收稿日期:2010-03-22 出版日期:2011-08-01
  • 通信作者: 施俊义

Expression of osteopontin in invasive breast carcinoma and its relationship with microvessel density

  1. 1.General Surgery Department, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
  • Received:2010-03-22 Published:2011-08-01
引用本文:

隋金珂, 王玥, 施俊义, 谢轶群, 李曦洲. 骨桥蛋白在浸润性乳腺癌组织中的表达及其与微血管密度的关系[J/OL]. 中华乳腺病杂志(电子版), 2011, 05(04): 426-433.

目的

探讨乳腺癌组织中不同骨桥蛋白(OPN)的表达水平及其与微血管密度的关系。

方法

采用免疫组织化学Envision 法检测89 例乳腺浸润性导管癌组织OPN 和CD34 的表达情况,分析其表达与病理特征的关系。 定性资料分析采用χ2 检验,定量资料分析采用t 检验。

结果

在89 例乳腺浸润性导管癌中,OPN 阳性表达率为57.30%(51/89)。 组织学分级Ⅰ、Ⅱ、Ⅲ级浸润性导管癌OPN 阳性表达率分别为27.27%(6/22)、66. 67%(24/36)、67. 74%(21/31),三者间差异有统计学意义(χ2 =10.780,P=0.005);有、无淋巴结转移者OPN 阳性表达率分别为74. 47%(35/47)和38.10%(16/42),伴有淋巴结转移者OPN 阳性表达率明显高于不伴转移者(χ2 =11.993,P=0.001)。 乳腺癌组织OPN 表达阴性、阳性组的肿瘤微血管密度(MVD)分别为(68.42±23.45)条/每高倍视野和(94.96±31.03)条/每高倍视野,二者间差异有统计学意义(t= 4.413,P=0.000)。

结论

OPN 在乳腺癌组织中的高表达与肿瘤血管的生成和肿瘤的浸润及转移有一定关系,针对OPN 的进一步研究可能为临床治疗乳腺癌转移提供新的方法。

Objective

To explore the expression of osteopontin in breast carcinoma and its relationship with microvascular density.

Methods

Envision immunohistochemical method was used to examine the expressions of osteopontin and CD34 in 89 invasive breast carcinoma cases and analyze their relationship with clinical pathological characteristics.Qualitative data were analyzed using chi-square test. Quantitative data were analyzed using t test.

Results

In the 89 cases of breast invasive ductal carcinoma,the positive rate of osteopontin was 57.30% (51/89). In grade I, II and III invasive ductal carcinoma patients,the positive rate of osteopontin was 27.27%(6/22), 66.67% (24/36) and 67.74%(21/31), respectively, with statistically significant difference between the three groups of patients(χ2=10.780,P=0.005). In patients with lymph nodes metastases and without lymph nodes metastases, the positive rate of osteopontin was 74. 47% (35/47) and 38. 10% (16/42)respectively, showing a high positive rate of osteopontin patients with lymph nodes metastases than without (χ2=11.993,P=0.001). The microvessel density was (68.42±23.45) per high-power field in patients with negative expression of osteopontin and (94.96±31.03)per high-power field in patients with positive expression of osteopontin, with statistically significant difference between the two groups (t=4.413, P=0.000).

Conclusion

High expression of osteopontin in breast cancer may have some relationship with tumor angiogenesis and tumor invasion and metastasis. Further study on the role of osteopontin in breast cancer blood vessels will provide a new method for the clinical treatment of breast cancer metastasis.

图1 骨桥蛋白阳性表达(免疫组织化学染色 ×200)
图2 骨桥蛋白阴性表达(免疫组织化学染色 ×200)
表1 骨桥蛋白阳性表达与临床特征的关系
表2 乳腺浸润性导管癌组织中骨桥蛋白表达与MVD 的关系
图3 骨桥蛋白阴性标本的CD34 表达(免疫组织化学染色 ×200)
图4 骨桥蛋白阳性标本的CD34 表达(免疫组织化学染色 ×200)
[1]
邵志敏.乳腺癌外科治疗发展趋势[J].外科理论与实践,2006, 11(2):89-91.
[2]
Senger DR, Wirth DF, Hynes RO, et al. Transformed mammalian cells secrete specific proteins and phosphoproteins[J].Cell,1979,16(4):885-893.
[3]
Weindner N,Folkman J,Pozza F,et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma[J]. J Nail Cancer Inst,1992,84(24):1875-1887.
[4]
Rudland PS, Higgins AP, Tanani ME, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer [J].Cancer Res,2002,62(12):3417-3427.
[5]
Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer[J]. Clin Cancer Res,2006,12(7):3337-3343.
[6]
Allan AL, George R, Vantyghem SA, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer[J]. Am J Pathol,2006,169(1): 233-246.
[7]
EI Tanani M, Barraclough R, Wilkinson MC, et al.Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tef-4[J]. Cancer Res,2001, 61(14):5619-5629.
[8]
Mi ZY, Guo HT, Philip Y, et al. Integrin linked kinase regulates oesteopontin dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells[J]. Carcinogenesis,2006,27(6):1134-1145.
[9]
Tang H, Wang J, Bai F,et al. Inhibition of osteopontin would suppress angiogenesis in gastric cancer[J]. Biochem Cell Biol,2007,85(1):103-110.
[10]
Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis [J]. Cancer Res, 2006,66(13):6638-6648.
[11]
Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms[J]. Cancer Res,2008,68(1):152-161.
[12]
Cavallam U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression[J]. Neuro Oncol,2000,50(1/2):63-70.
[13]
孟令华,刘巍,宋丽楠,等.BCSG1、C-erbB-2、VEGF 表达与乳腺癌临床病理因素相关性研究[J/CD].中华乳腺病杂志:电子版,2007,1(4):29-36.
[14]
Hirama M, Takahashi F, Takahashi K, et al .Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth [J]. Cancer Lett, 2003,198(1):107-117.
[15]
Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms[J]. Cancer Res,2008,68(1):152-161.
[16]
Takahash F, Akatagawa S, Fukumoto H, et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice[J]. Int J Cancer,2002,98(5):707-712.
[17]
Cheriyath V,Hussein MA.Osteopontin,angiogenesis and multiple myeloma[J].Leukemia,2005,19(12):2203-2205.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
阅读次数
全文


摘要